Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Operating Leases: 2023-2024

Historic Operating Leases for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $39.0 million.

  • Monte Rosa Therapeutics' Operating Leases fell 10.30% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year decrease of 10.30%. This contributed to the annual value of $39.0 million for FY2024, which is 9.04% down from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Operating Leases is $39.0 million, which was down 9.04% from $42.9 million recorded in FY2023.
  • Monte Rosa Therapeutics' Operating Leases' 5-year high stood at $42.9 million during FY2023, with a 5-year trough of $39.0 million in FY2024.
  • Its 2-year average for Operating Leases is $40.9 million, with a median of $40.9 million in 2023.
  • Data for Monte Rosa Therapeutics' Operating Leases shows a maximum YoY decreased of 9.04% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Operating Leases (Yearly) stood at $42.9 million in 2023, then fell by 9.04% to $39.0 million in 2024.